Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
A session filmed at the 64th ASH Annual Meeting and Exposition, featuring leading experts David Sallman and Andrew Brunner, who discuss advances in treatment approaches for lower-risk and higher-risk MDS, clinical trial updates, and more.
Welcome to The MDS Sessions brought to you by the Video Journal of Hematological Oncology (VJHemOnc). This exclusive session features leading experts David Sallman, MD, Moffitt Cancer Center, Tampa, FL, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA, who share key updates in myelodysplastic syndromes (MDS) at the 64th ASH Annual Meeting and Exposition. Topics covered include advances in treatment approaches for lower-risk and higher-risk MDS as well as for patients with hypomethylating agent (HMA) failure. The experts further discuss the role of novel classification systems, novel targets, and considerations for transplant.
The MDS Channel on VJHemOnc receives independent medical education support from:
